These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16113096)

  • 1. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
    Duncan R; Vicent MJ; Greco F; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer conjugates: nanosized medicines for treating cancer.
    Vicent MJ; Duncan R
    Trends Biotechnol; 2006 Jan; 24(1):39-47. PubMed ID: 16307811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
    Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer-protein and polymer-drug conjugates in cancer therapy.
    Thanou M; Duncan R
    Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer conjugates as anticancer nanomedicines.
    Duncan R
    Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing polymer conjugates as lysosomotropic nanomedicines.
    Duncan R
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):56-60. PubMed ID: 17233601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.
    Duncan R; Vicent MJ
    Adv Drug Deliv Rev; 2010 Feb; 62(2):272-82. PubMed ID: 20005271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymer therapeutics: concepts and applications.
    Haag R; Kratz F
    Angew Chem Int Ed Engl; 2006 Feb; 45(8):1198-215. PubMed ID: 16444775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F; Vicent MJ
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dawning era of polymer therapeutics.
    Duncan R
    Nat Rev Drug Discov; 2003 May; 2(5):347-60. PubMed ID: 12750738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
    Paul A; Vicent MJ; Duncan R
    Biomacromolecules; 2007 May; 8(5):1573-9. PubMed ID: 17419585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics.
    Gaspar R; Duncan R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1220-31. PubMed ID: 19682513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
    Gligorov J; Lotz JP
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable amphiphilic polymer-drug conjugate micelles.
    Hu X; Jing X
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1079-90. PubMed ID: 19645633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.
    Duncan R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1131-48. PubMed ID: 19699249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.